论文部分内容阅读
目的探讨急性脑梗死尿激酶静脉溶栓治疗的疗效及其安全性。方法采用开放性临床研究,将发病12 h内60例急性脑梗死患者随机分为两组,溶栓治疗组30例,常规治疗组30例。结果溶栓组治疗基本痊愈率为50.0%,总显效率为91.7%,脑出血并发症为5.5%,脑出血病死率为2.8%;常规治疗组基本痊愈率为14.0%,总显效率为66.6%,无一例死于脑出血。结论急性脑梗死发病12 h内尿激酶静脉溶栓治疗疗效较好,但脑出血并发症明显增多。
Objective To investigate the efficacy and safety of intravenous thrombolytic therapy of urokinase in acute cerebral infarction. Methods Sixty patients with acute cerebral infarction within 12 hours after onset were randomly divided into two groups: thrombolytic therapy group (30 cases) and conventional therapy group (30 cases). Results The basic cure rate was 50.0%, the total effective rate was 91.7%, the complications of intracerebral hemorrhage was 5.5% and the fatality rate of intracerebral hemorrhage was 2.8%. The basic cure rate was 14.0% and the total effective rate was 66.6 %, No one died of cerebral hemorrhage. Conclusion Intravenous thrombolytic therapy of urokinase within 12 hours after onset of acute cerebral infarction is effective, but the complication of intracerebral hemorrhage is obviously increased.